All News
The third SARS-CoV-2 vaccine in IMID (RA, SpA, PsA, UC, CD) patients on immunosuppression improves the serologic response follow the first two vaccine doses and allowed them to close the gap compared to the two-dose vaccinated controls #EULAR2022 @RheumNow OP0192 Jyssum et al
Dr. Antoni Chan synovialjoints ( View Tweet)
For psoriasis +MSK pain, should we be chasing synovitis/enthesitis on ultrasound?
PsO pts with MSK pain n=79
USS inflamm in 47%
Site-spec correlate only OR 3.1
Even if we act on USS:
PsA Rx is systemic, so overall impression is good enough anyway?
POS0131 #EULAR2022 @RheumNow https://t.co/O3P7J2Rskw
David Liew drdavidliew ( View Tweet)
Are wearable devices useful in assessing physical activity in rheumatic diseases?
Meta-analysis showed pts with rheumatic diseases reached recommended threshold for moderate to vigorous physical activity but not daily steps.
@RheumNow #EULAR2022 POST#POS0163
Robert B Chao, MD doctorRBC ( View Tweet)
Schmitt et al. Pharmacokinetic study of IV tocilizumab in 24 patients with known GCA. Using 6mg/kg or 7mg/kg. Effective on lab measures and no GCA flares. @RheumNow #EULAR2022 POS0268 https://t.co/uhxfGZvYTw
Richard Conway RichardPAConway ( View Tweet)
OP0283 MMF vs CYP for induction of remission #LupusNephritis. Real world Beijing cohort. n=360 50% Rx naïve. CRR at 1 yr was more common in MMF, esp proliferative LN. GI & infection more common w/CYP. Lower prednisone dose and Urinary protein seen in MMF #EULAR2022 @rheumnow https://t.co/4P43j1rApF
TheDaoIndex KDAO2011 ( View Tweet)
Dougados et al. MACE in tofa clinical programme. Baseline CV risk important. Overall MACE IR 0.38 [0.26-0.54]. MACE IR lower than in ORAL Surveillance in CV enriched pop 0.72 [0.46-1.09]. @RheumNow #EULAR2022 OP0264 https://t.co/lGTTEx0X5p https://t.co/MvD6kjkpse
Links:
Richard Conway RichardPAConway ( View Tweet)
#EULAR2022 POS0210
RNA sequencing in 11 RA-ILD patients vs 9 RA pts
⭐️Distinct gene expression in RA-ILD with type 1 IFN response, neutrophil activation, and degranulation and CCR1 chemokine interactions
@RheumNow
@fahidalghanim https://t.co/FIrZfzZV1C
Eric Dein ericdeinmd ( View Tweet)
TNFi were going to unleash a TB wave
What has the biologic era really done for TB & opportunistic infx?
Hospitalised data from Western Australia post-2003:
TB actually not up (screening)
myocoses were up (no screening)
Dare I say it: screening works
OP0274 #EULAR2022 @RheumNow
David Liew drdavidliew ( View Tweet)
#EULAR2022 – Day 2 Report
A full day at EULAR with oral and poster presentations of abstracts in the morning and a plethora of scientific (review) sessions in the afternoon. The latter covering topics like sarcoidosis, Still’s disease, and fibromyalgia.
https://t.co/dpq5Het2rN https://t.co/NIfkjhHw86
Links:
Dr. John Cush RheumNow ( View Tweet)
#EULAR2022 POS0256 by @CaoilfhionnMD, @DrLisaCS, @JuliePaikMD from @HopkinsRheum
10% of pts seronegative for COVID antibodies after vaccination
⭐️Risk factors: Non-white, J&J vaccine, MMF, RTX, GC, combination Rx, not-withholding peri-vaccination immunosuppression
@Rheumnow https://t.co/Izd4QJlOWH
Eric Dein ericdeinmd ( View Tweet)
OP0280 WIN-lupus study eval if #SLE LN pts in remission can stop Rx. In pts who continued vs. stopped Rx: renal relapse 12% vs. 27%, p=0.08 and severe SLE flare 12 vs 32%, p=0.03; pts relapsing had inc baseline UPCR/SLEDAI score; +APS; lower lymphs/C3 . #EULAR2022 @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
Torgashina et al Rituximab in Sjogrens ILD. ILD first manifestation of Sjogrens in 26%. Rituximab improvement in 37% and stabilisation in 47%. @RheumNow #EULAR2022 POS0710 https://t.co/CCnPVrTGfI
Richard Conway RichardPAConway ( View Tweet)
#EULAR2022 OP0278:
Increase in risk of CVA compared to general population ~1.2x risk
⭐️This is unchanged between the pre-biologic (1972-1998) and the post-biologic treatment era
⭐️Interesting finding: smoking rate same over time in RA, despite decr in Norway in gen pop
@Rheumnow https://t.co/r8QsJABfvx
Eric Dein ericdeinmd ( View Tweet)
Charles-Schoeman et al. ORAL Surveillance. PE risk factors - History VTE, antidepressant use, obesity, steroids, male, age, OCP/HRT. PPI protective @RheumNow #EULAR2022 POS0239 https://t.co/fDLKrpvpgI
Richard Conway RichardPAConway ( View Tweet)
Pan et al. SPI-62 (11beta-hydroxysteroid dehydrogenase inhibitor) minimises steroid side effects in animal studies. Now going on to a clinical trial in PMR. Exciting as steroid adverse events are a huge problem in PMR/GCA @RheumNow #EULAR2022 POS1332 https://t.co/NEoIx971jS
Richard Conway RichardPAConway ( View Tweet)
Can we predict VTEs from JAKi for RA at all?
Baseline elevated D-dimer pts who go on to develop VTE
(but not baseline CRP, so not just general inflamm)
Questions raised about effect modification for VTE following JAKi too. This story not yet done
OP0269 #EULAR2022 @RheumNow https://t.co/ErDcFpXXUl
David Liew drdavidliew ( View Tweet)
#EULAR2022 OP0277 MSK IRAE from Checkpoint inhibitors
⭐️118 pts w MSK complaints
76% w arthralgias/myalgias, 30% with inflammatory rheumatic features
Most grade 1/2, 2 grade 4 (myositis)
23 (19.5%) required d/c, time of resolution ~3 mos, 20% persistence at end of study
@RheumNow https://t.co/SINqmmjsLq
Eric Dein ericdeinmd ( View Tweet)
Leng et al. Tocilizumab biosimilar BAT1806/BIIB800 vs originator in MTX-IR RA. Not surprisingly they look the same. Great to see given negative clinical impact of recent supply problems with originator. @RheumNow #EULAR2022 POS0287 https://t.co/EqwINwcm7M
Richard Conway RichardPAConway ( View Tweet)
Tomelleri @tomelleri_a et al. GCA. Tocilizumab weekly x 1 year, then every other week x 1 year, then stop. 2 PMR flares during toc. 1 month post-stop 100% remission. 6 months post-stop 24% GCA flare! Some patients seem to need indefinite toc @RheumNow #EULAR2022 POS0266 https://t.co/8I5GQ08HDr
Richard Conway RichardPAConway ( View Tweet)
Long-term low-dose steroids for RA: can it be weaned?
Weaning after 2y of blinded add-on in RA:
either PNL 5mg/d or placebo
No substantial evidence of adrenal insufficiency
- symptoms same
- cortisol/ACTH same
It's never too late to wean the pred!
OP0270 #EULAR2022 @RheumNow https://t.co/jp2ZOlAEnb
David Liew drdavidliew ( View Tweet)